AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen Inc (NASDAQ: AMGN) Delayed: 379.78 +3.43 (0.91%)
Previous Close $376.35    52 Week High $176.85 
Open $379.15    52 Week Low $133.64 
Day High $382.49    P/E 57.20 
Day Low $376.08    EPS $6.64 
Volume 3,234,871